Compositions and methods for treating or preventing diseases associated with oxidative stress
Abstract
Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A stable pharmaceutical composition for use in corneal collagen cross-linking, comprising (a) between about 0.015% to about 5% sodium iodide by weight, (b) 0.5. % riboflavin by weight, or salts thereof, and (c) a pharmaceutically-acceptable excipient appropriate for ocular administration, wherein the pharmaceutical composition maintains a basic pH that permits iodide ion to catalytically break hydrogen peroxide into water and oxygen.Join the waitlist — get patent alerts
Track US2023285451A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.